Abiopharma

🔍 Carol Nutter (Executive)

Company: Claritev Corp (CTEV)

Report Date: 2026-02-18

Detailed Transactions and Holdings:

• Acquired 1,884 shares of Class A common stock (Direct)
  Date: 2026-02-18 | Code: A | equity_swap_involved: 0 | shares_owned_after: 30,748.00 | transaction_form_type: 4 | Footnotes: F1

Footnotes:

• F1: Represents earned performance-based restricted stock units ("PSUs"), which will vest in the first quarter of 2027, subject to Participant's continued employment with Claritev Corporation (the "Company"). The PSUs were earned after certification by the Compensation Committee of Board of Directors of the Company upon the satisfaction of revenue-based performance criteria underlying an award of PSUs granted to the Reporting Person on March 1, 2024 under the terms of the Company's 2020 Omnibus Incentive Plan and the applicable PSU award agreement. The award provides a performance condition based on the Company's revenue for the two-year performance period ending December 31, 2025. The Company's total revenue for the two-year performance period as compared to target resulted in Participant earning 67% of the awarded PSUs based on revenue.